Skip to main content
. 2022 Jan 27;14(3):656. doi: 10.3390/cancers14030656

Table 2.

Participant characteristics.

Participant Characteristic mEHT Control p-Value
106 (50.5%) 104 (49.5%)
HIV Status Positive 52 (49.1%) 55 (52.9%) p = 0.579
Negative 54 (50.9%) 49 (47.1%)
Age Group <50 years 52 (49.1%) 46 (44.2%) p = 0.483
≥50 years 54 (50.9%) 58 (55.8%)
ECOG 0 3 (2.8%) 7 (6.7%) p = 0.184
1 103 (97.2%) 97 (93.3%)
Race African 98 (92.5%) 97 (93.3%) p = 0.335
Caucasian 4 (3.8%) 1 (1.0%)
Indian 0 (0.0%) 0 (0.0%)
Asian 0 (0.0%) 0 (0.0%)
Mixed Race 4 (3.8%) 6 (5.8%)
Education Primary 45 (43.3%) 50 (49.0%) p = 0.334
Secondary 55 (52.9%) 51 (50.0%)
Tertiary 4 (3.8%) 1 (1.0%)
Employment Unemployed 83 (78.3%) 82 (78.8%) p = 0.923
Employed 23 (21.7%) 22 (21.2%)
FIGO IIB 40 (37.7%) 36 (34.6%) p = 0.895
Staging IIIA 1 (0.9%) 1 (1.0%)
IIIB 65 (61.3%) 67 (64.4%)
Histological Grade 1 7 (6.9%) 4 (4.1%) p = 0.759
2 70 (69.3%) 67 (69.1%)
3 24 (23.8%) 26 (26.8%)
Tumour Dimensions (cm) Median 7 7.1 p = 0.1429
Min 2.7 1.8
Max 11.7 14.87
Tumour SUV Median 18.07 19.26 p = 0.7769
Min 7.01 6.07
Max 63.25 97
HB (g/dL) Median 10.9 11 p = 0.9424
Min 5.7 5.2
Max 16.2 16.2
Age Median 49.2 50.6 p = 0.3665
Min 27.3 29.2
Max 70.8 74.8
BMI Median 27 26.5 p = 0.3883
Min 15 15
Max 49 41.7

Abbreviations: BMI: Body Mass Index; ECOG: Eastern Cooperative Oncology Group; FIGO: Fédération Internationale de Gynécologie et d’Obstétrique; HB: Haemoglobin; HIV: Human Immunodeficiency Virus; mEHT: Modulated Electro-Hyperthermia; SUV: Standard Uptake Value.